Glenmark Pharmaceuticals announced that the Ministry of Health of the Russian Federation has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis, and the company expects to launch the nasal spray in Russia in the first quarter of fiscal year 2021-22. Glenmark Pharmaceuticals Senior … [Read more...] about Ryaltris nasal spray approved by Russian Ministry of Health
Business
Microbion gets additional funding from CFF for inhaled pravibismane
According to Microbion Corporation, the company has received up to $1.8 million from the Cystic Fibrosis Foundation to fund toxicology studies to support an IND for the company's pravibismane inhalation suspension for the treatment of lung infections in CF patients. CFF had previously provided a grant worth up to $5.6 million for development of the inhaled … [Read more...] about Microbion gets additional funding from CFF for inhaled pravibismane
Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine
Seelos Therapeuticse has announced an additional amendment to its 2018 agreement with Vyera Pharmaceuticals (now Phoenixus) in order for the company to repurchase 9% of royalties payable on any future net sales of SLS-002 intranasal racemic ketamine. A previous amendment to the agreement that allowed Seelos to make cash and stock payments instead of a milestone … [Read more...] about Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine
CEBINA partners with Ursapharm Arzneimittel to develop azelastine nasal spray for the treatment of COVID-19
The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm's Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a patent application for the use of azelastine to treat COVID-19 and that it was looking for partners … [Read more...] about CEBINA partners with Ursapharm Arzneimittel to develop azelastine nasal spray for the treatment of COVID-19
Windtree gets US patent covering its aerosol delivery system
The US Patent and Trademark Office has issued US Patent No. 10,874,818, titled "Aerosol Delivery System," covering technology used in the delivery of Windtree Therapeutics' Aerosurf aerosolized KL4 surfactant, Windtree said. The company redesigned the aerosol delivery system (ADS) platform prior to initiating Phase 3 studies of Aerosurf after problems with the … [Read more...] about Windtree gets US patent covering its aerosol delivery system
Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm). According to Tonix, patents included in the license provide exclusivity through 2031 in the US and Europe. … [Read more...] about Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix's PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary fibrosis. SarcoMed's lead candidate, SM001, is an inhaled DNase 1 formulation that the … [Read more...] about SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics' AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension in China, Hong Kong, Macau, and Taiwan, Aerami has announced. Aerami will continue to develop AER-901 for … [Read more...] about Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Herantis partners with Nanoform on intranasal biologics formulation projects
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform's biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics in November 2020. Herantis is developing CDNF for the treatment of Parkinson’s … [Read more...] about Herantis partners with Nanoform on intranasal biologics formulation projects
AuraVax licenses intranasal vaccine technology from University of Houston
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier this year, the company announced that it had licensed liposomal STING agonist technology from Massachusetts … [Read more...] about AuraVax licenses intranasal vaccine technology from University of Houston